SINGAPORE INSTITUTE OF ADVANCED MEDICINE HOLDINGS LTD.

(Incorporated in the Republic of Singapore on 24 November 2011)
(Company Registration Number: 201134046D)

USE OF PROCEEDS FROM THE PLACEMENT OF AN AGGREGATE OF 19,748,000 NEW SHARES AT A PLACEMENT PRICE OF S$0.035 PER SHARE TO CERTAIN SUBSCRIBERS

Unless otherwise defined or the context otherwise requires, all capitalised terms used herein bear the same meanings as in the Announcements (as defined below).

The Board of Directors (the "**Board**") of Singapore Institute of Advanced Medicine Holdings Ltd. (the "**Company**", together with its subsidiaries, collectively, the "**Group**") refers to the Company's announcements dated 30 September 2025, 9 October 2025 and 15 October 2025 (collectively, the "**Announcements**") relating to, *inter alia*, the placement exercise of an aggregate of 19,748,000 new Shares ("**Placement Shares**") at a placement price of S$0.035 per Placement Share to certain subscribers, which has been completed on 15 October 2025 ("**Placement**").

The Board wishes to update that the Net Placement Proceeds of approximately S$644,000 have on 16 January 2026 been fully utilised to fund the general working capital of the Group, in accordance with its intended use as set out in the Announcements. The Company acknowledges that there was an oversight to not make an immediate announcement when the Net Placement Proceeds was materially utilised.

The breakdown of the use of Net Placement Proceeds for general working capital is as follows:

Use of Net Placement Proceeds	**Amount utilised as at the date of this announcement**	**Balance amount of Net Placement Proceeds as at the date of this announcement**
	(S$'000)	**(S$'000)**
General Working Capital		
(i) Maintenance fees for medical equipment	644	-
Total	**644**	**-**

BY ORDER OF THE BOARD

Dr Djeng Shih Kien
Executive Director and Chief Executive Officer
2 February 2026

Singapore Institute of Advanced Medicine Holdings Ltd. (the "**Company**") was listed on Catalist of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") on 16 February 2024. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**").

This announcement has been reviewed by the Sponsor. It has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms. Ng Shi Qing, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.